Sign in
Not yet taking people in United StatesPhase 4

How Healthy Adults Respond to the Nasal Flu Vaccine

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
20 people, planned
Starts
1 Dec 2026
Expected to end
30 Jun 2031
Type of study
Interventional
Treatments tested
  • FluMist (Live Attenuated Influenza Vaccine)
Record updated
13 October 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Healthy adults aged 18 to 65 years
  • Non-smokers (no smoking or vaping within the past 6 months)
  • No chronic lung disease or significant chronic medical conditions
  • No current or recent (within 1 month) upper or lower respiratory infection
  • Able and willing to provide informed consent
  • Have not received the current seasonal influenza vaccine
  • Able to comply with study procedures and follow-up visits

Who cannot take part

  • Receipt of influenza vaccine during the current season or within the past 2 weeks
  • Receipt of another live vaccine within 4 weeks prior to enrollment or planned during study period
  • Use of influenza antiviral medications (e.g., oseltamivir, zanamivir) within 48 hours prior to vaccination or planned use within 14 days after vaccination
  • Immunocompromised individuals (including HIV/AIDS, immunosuppressive therapy, chemotherapy, or primary immunodeficiency)
  • Chronic medical conditions including asthma, chronic lung, liver, kidney, neurologic, hematologic, metabolic, or significant cardiovascular disease (except isolated hypertension)
  • History of chronic sinusitis or significant nasal allergies requiring frequent or daily treatment
  • Acute moderate or severe illness at time of enrollment, with or without fever
  • History of severe allergic reaction to influenza vaccine or any component of FluMist (including egg allergy if applicable)
  • History of Guillain-Barré syndrome following influenza vaccination
  • Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results
  • Age under 18 or over 65 years
  • Pregnancy or breastfeeding
  • Prisoners
  • Non-English speaking individuals

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Shanna H Graves, AASNot yet recruiting

About the trial

What the trial wants to find out

This study is looking at how the immune system in the nose responds after receiving the FluMist nasal flu vaccine in healthy adults. FluMist is an FDA-approved influenza vaccine that is given as a nasal spray.

Read full original descriptionShow less

Healthy volunteers aged 18 to 65 who do not have chronic medical conditions, do not smoke, and have not recently received a flu vaccine will be enrolled. Participants will have three study visits over approximately one week. At the first visit, participants will be screened, give informed consent, and receive the FluMist vaccine. Nasal swabs and a gentle saline nasal wash will be collected before vaccination and again at two and four days after vaccination.

The samples collected will be used to study changes in immune cells, proteins, and viral activity in the nose using laboratory techniques such as gene expression and protein analysis. This information may help researchers better understand how flu vaccines work at the site where infection begins and may support the development of improved vaccines in the future.

There is no direct medical benefit expected for participants. Participation is voluntary, and all study procedures will be performed by trained clinical staff.

The group in the trial

  • Healthy Adults Receiving Intranasal FluMist VaccinationTreatment being tested

    Participants in this single-arm study will receive the FDA-approved live attenuated influenza vaccine (FluMist) administered intranasally according to standard dosing guidelines. All participants will undergo nasal sampling procedures, including nasal swabs and nasal wash, at baseline prior to vaccination and at approximately 2 and 4 days following vaccination. Samples will be collected to evaluate temporal changes in mucosal immune and epithelial responses using molecular and proteomic analyses. No placebo or comparator intervention is used.

    Treatment: FluMist (Live Attenuated Influenza Vaccine)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Characterizing Local Mucosal Responses to Live Attenuated Influenza Vaccine in Healthy Adults
Criteria questions
Built from NCT07726862, who can take part
Record updated
13 October 2026